Cargando…

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Detalles Bibliográficos
Autores principales:	Borrero-Palacios, A., Cebrián, A., Gómez del Pulgar, M. T., García-Carbonero, R., Garcia-Alfonso, P., Aranda, E., Elez, E., López-López, R., Cervantes, A., Valladares, M., Nadal, C., Viéitez, J. M., Guillén-Ponce, C., Rodríguez, J., Hernández, I., García, J. L., Vega-Bravo, R., Puime-Otin, A., Martínez-Useros, J., Del Puerto-Nevado, L., Rincón, R., Rodríguez-Remírez, M., Rojo, F., García-Foncillas, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522500/ https://www.ncbi.nlm.nih.gov/pubmed/31097738 http://dx.doi.org/10.1038/s41598-019-43809-z

Ejemplares similares

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
por: Borrero-Palacios, A., et al.
Publicado: (2019)

The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
por: Martinez-Useros, J., et al.
Publicado: (2018)

Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 “STARD Compliant”
por: Martinez-Useros, J., et al.
Publicado: (2015)

DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer
por: Martinez-Useros, Javier, et al.
Publicado: (2014)

UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept
por: Martinez-Useros, Javier, et al.
Publicado: (2017)

Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study
por: del Puerto-Nevado, Laura, et al.
Publicado: (2016)

Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer
por: Gómez del Pulgar, Teresa, et al.
Publicado: (2016)

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy
por: del Puerto-Nevado, L, et al.
Publicado: (2014)

Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer
por: Aguilera, Oscar, et al.
Publicado: (2016)

UNR/CSDE1 Expression Is Critical to Maintain Invasive Phenotype of Colorectal Cancer through Regulation of c-MYC and Epithelial-to-Mesenchymal Transition
por: Martinez-Useros, Javier, et al.
Publicado: (2019)

Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance
por: Rio-Vilariño, Anxo, et al.
Publicado: (2021)

Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes
por: Manzanares-Martin, Barbara, et al.
Publicado: (2021)

Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer
por: Cristóbal, I, et al.
Publicado: (2014)

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015
por: Aranda, E., et al.
Publicado: (2015)

The Prognosis Value of PIWIL1 and PIWIL2 Expression in Pancreatic Cancer
por: Li, Weiyao, et al.
Publicado: (2019)

New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review
por: Garcia-Carbonero, Nuria, et al.
Publicado: (2018)

The Clinical Significance of PIWIL3 and PIWIL4 Expression in Pancreatic Cancer
por: Li, Weiyao, et al.
Publicado: (2020)

Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)
por: Elez, E., et al.
Publicado: (2021)

Obesity and colorectal cancer: molecular features of adipose tissue
por: Martinez-Useros, Javier, et al.
Publicado: (2016)

The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer
por: Martinez-Useros, Javier, et al.
Publicado: (2016)

Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?
por: Martinez-Useros, Javier, et al.
Publicado: (2016)

The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1
por: Anania, Jessica C., et al.
Publicado: (2018)

Clinical guideline SEOM: hepatocellular carcinoma
por: Sastre, J., et al.
Publicado: (2015)

KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
por: Garcia-Carbonero, Nuria, et al.
Publicado: (2020)

Choline kinase inhibition induces exacerbated endoplasmic reticulum stress and triggers apoptosis via CHOP in cancer cells
por: Sanchez-Lopez, E, et al.
Publicado: (2013)

Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
por: Abajo, A, et al.
Publicado: (2012)

Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
por: García-Alfonso, P., et al.
Publicado: (2020)

Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2
por: Wines, Bruce D., et al.
Publicado: (2021)

The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance
por: Martinez-Useros, Javier, et al.
Publicado: (2021)

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
por: Cebrián, Arancha, et al.
Publicado: (2017)

Patient Characteristics Associated with Growth of Patient-Derived Tumor Implants in Mice (Patient-Derived Xenografts)
por: Hernández Guerrero, Tatiana, et al.
Publicado: (2023)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain
por: Garcia-Medina, Jose J., et al.
Publicado: (2022)

Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review
por: García-Foncillas, J, et al.
Publicado: (2017)

Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment
por: Martinez-Useros, Javier, et al.
Publicado: (2017)

Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients
por: Abajo, A, et al.
Publicado: (2010)

P1718: A PROSPECTIVE MULTICENTER SURVEY ABOUT THE USE OF NEW TECHOLOGIES AND DIGITAL HEALTH TOOLS IN PATIENTS (PTS) WITH HEMATOLOGICAL MALIGNANCIES
por: Lopez-Garcia, A., et al.
Publicado: (2022)

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
por: Grasselli, J, et al.
Publicado: (2017)

Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments
por: Martinez-Useros, Javier, et al.
Publicado: (2021)

Iron-Dependent Cell Death: A New Treatment Approach against Pancreatic Ductal Adenocarcinoma
por: Lopez-Blazquez, Carlos, et al.
Publicado: (2023)

A Novel PiRNA Enhances CA19-9 Sensitivity for Pancreatic Cancer Identification by Liquid Biopsy
por: Li, Weiyao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9hgsojhumefkmo3c5bj2060ri8